Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 02, 2024

MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed CLL: Long-Term Efficacy and ctDNA Analysis



Additional Info

Disclosure statements are available on the authors' profiles:

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
Blood 2024 Apr 15;[EPub Ahead of Print], M Fürstenau, A Giza, J Weiss, F Kleinert, S Robrecht, F Franzen, J Stumpf, P Langerbeins, O Al-Sawaf, F Simon, AM Fink, C Schneider, E Tausch, J Schetelig, P Dreger, S Böttcher, K Fischer, KA Kreuzer, M Ritgen, A Schilhabel, M Brüggemann, S Stilgenbauer, B Eichhorst, M Hallek, P Cramer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading